Previous in-vitro data pointed out lithium, an activator of the β-catenin signalling pathway, as a modulator of HIV-1 transcription. We assessed the effect of in-vivo administration of lithium on viral latency modulation in nine antiretroviral therapy (ART)-suppressed HIV-1-infected individuals. We found that lithium carbonate treatment was able to transiently repress HIV-1 residual expression in CD4 T cells in vivo, which led to a concomitant short-term decrease in the proviral reservoir size.
No takes yet. Share an insight, caveat, or question.
Puertas et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: